Drugs / KP-dHGF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00797706 | Nov 2008 → Mar 2010 | chronic ulcer of skin | Kringle Pharma Europe AB | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KP-dHGF | “A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted...” NCT00797706 ↗ |
| Known as | CHRONSEAL | “A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted...” NCT00797706 ↗ |
| Modality | Protein / enzyme biologic | “5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor” NCT00797706 ↗ |
| Route | Topical | “topical administration” NCT00797706 ↗ |